Amifostine

drugbox
IUPAC_name = 2-(3-aminopropylamino)ethylsulfanyl
phosphonic acid

---

CAS_number = 20537-88-6
ATC_prefix = V03
ATC_suffix = AF05
PubChem = 2141
ChemSpiderID = 2056
DrugBank = APRD00021
C = 5 |H = 15 |N = 2 |O = 3 |P = 1 |S = 1
molecular_weight = 214.224 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life = 8 minutes
pregnancy_US = C
legal_US = Rx-only
routes_of_administration = Intravenous

Amifostine is a cytoprotective adjuvant used in cancer chemotherapy involving DNA-binding chemotherapeutic agents. Also commonly known as WR-1065 in its active form. It is marketed by MedImmune under the trade name Ethyol.

Amifostine is used therapeutically to reduce the incidence of neutropenia-related fever and infection induced by DNA-binding chemotherapeutic agents including alkylating agents (e.g. cyclophosphamide) and platinum-containing agents (e.g. cisplatin). It is also used to decrease the cumulative nephrotoxicity associated with platinum-containing agents. Amifostine is also indicated to reduce the incidence of xerostomia in patients undergoing radiotherapy for head and neck cancer.

Of note, amifostine was originally indicated to reduce the cumulative renal toxicity from cisplatin in non-small cell lung cancer. However, while nephroprotection was observed, the fact that amifostine could protect tumors could not be excluded. Given better treatment options for non-small cell lung cancer, this indication for non-small cell lung cancer was withdrawn in 2005.

Amifostine is an organic thiophosphate prodrug which is hydrolysed "in vivo" by alkaline phosphatase to the active cytoprotective thiol metabolite. The selective protection of non-malignant tissues is believed to be due to higher alkaline phosphatase activity, higher pH, and vascular permeation of normal tissues.

Amifostine can only be administered intravenously, after reconstitution with normal saline. Infusions lasting less than 15 minutes decrease the risk of adverse effects. The patient should be well-hydrated before administration.

Adverse effects

Common side effects of amifostine include hypocalcemia, diarrhea, nausea, vomiting, sneezing, somnolence, and hiccoughs. Serious side effects include: hypotension (found in 62% of patients), erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis, immune hypersensitivity syndrome, erythroderma, anaphylaxis, and loss of consciousness (rare).

Contraindications

Contraindications to receiving amifostine include hypersensitivity to amifostine, aminothiol compounds, and mannitol.